FLOT4 — Perioperative FLOT Versus ECF/ECX in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

Phase 2/3 · 2019 · Gastric Cancer, Gastroesophageal Junction Cancer

Design

Randomized perioperative trial comparing FLOT versus the ECF/ECX regimen, each given before and after surgery.

Population

Resectable gastric or GEJ adenocarcinoma (cT2 or higher and/or node-positive).

Primary Endpoint

overall survival (OS)

Key Result

Median OS 50 vs 35 months (HR 0.77); higher pathologic complete/near-complete response with FLOT.

Guideline Impact

NCCN category 1 perioperative regimen for resectable gastric/GEJ adenocarcinoma